000304116 001__ 304116
000304116 005__ 20251203110754.0
000304116 0247_ $$2doi$$a10.3238/arztebl.m2025.0081
000304116 0247_ $$2pmid$$apmid:40493882
000304116 0247_ $$2altmetric$$aaltmetric:179633559
000304116 037__ $$aDKFZ-2025-01779
000304116 041__ $$aEnglish
000304116 082__ $$a610
000304116 1001_ $$aClaassen, Kevin$$b0
000304116 245__ $$aThe Probability of Remaining Under Active Surveillance for Localized Prostate Cancer: An Analysis of Young Patients in the Framework of the Multicenter ProjuMa Registry Study.
000304116 260__ $$aKöln$$bDt. Ärzte-Verl.$$c2025
000304116 3367_ $$2DRIVER$$aarticle
000304116 3367_ $$2DataCite$$aOutput Types/Journal article
000304116 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764756458_1331669
000304116 3367_ $$2BibTeX$$aARTICLE
000304116 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304116 3367_ $$00$$2EndNote$$aJournal Article
000304116 500__ $$aGerman Cancer ResearchCenter (DKFZ), Epidemi-ological Cancer Registry
000304116 520__ $$aAfter a diagnosis of prostate cancer, the 15-year cancer-specific survival probability is high; in suitable patients, active surveillance lessens the side effects of curative treatment. Limited evidence is available on the continuation of active surveillance in young prostate cancer patients in Germany.Using data that were reported, as required by law, to the population-based cancer registries of the German federal states of North Rhine-Westphalia, Baden-Württemberg, and Rhineland- - Palatinate, we studied the course of 732 patients under 60 years of age who were under active surveillance after receiving a diagnosis of low-risk localized prostate cancer (ISUP grade 1 or 2) in the years 2016-2021.The median duration of follow-up was 28 months. 64% [61%; 68%] of the patients were still under active surveillance at two years; this was true for 66% [62%; 70%] of those with ISUP grade 1 disease, 46% [37%; 58%] of those with ISUP grade 2 disease, and 72% [63%; 83%] of those for whom no Gleason grading was available. 62% of discontinuations occurred without any documented progression and without a documented patient-initiated decision.The two-year probability of young prostate cancer patients remaining under active surveillance was lower in Germany than in other countries. The cancer registries mostly received no information concerning the clinical rationale for the discontin uations. The potentially incomplete reporting of reasons for discontinuing active surveillance suggests that clinical reporting practices should be improved.
000304116 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000304116 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304116 650_2 $$2MeSH$$aHumans
000304116 650_2 $$2MeSH$$aMale
000304116 650_2 $$2MeSH$$aProstatic Neoplasms: mortality
000304116 650_2 $$2MeSH$$aProstatic Neoplasms: therapy
000304116 650_2 $$2MeSH$$aProstatic Neoplasms: epidemiology
000304116 650_2 $$2MeSH$$aProstatic Neoplasms: diagnosis
000304116 650_2 $$2MeSH$$aProstatic Neoplasms: pathology
000304116 650_2 $$2MeSH$$aRegistries: statistics & numerical data
000304116 650_2 $$2MeSH$$aGermany: epidemiology
000304116 650_2 $$2MeSH$$aWatchful Waiting: statistics & numerical data
000304116 650_2 $$2MeSH$$aMiddle Aged
000304116 650_2 $$2MeSH$$aAdult
000304116 650_2 $$2MeSH$$aSurvival Rate
000304116 7001_ $$aJustenhoven, Christina$$b1
000304116 7001_ $$0P:(DE-He78)a8ce1da94e91296e574e4849cfabd230$$aHermann, Silke$$b2$$udkfz
000304116 7001_ $$0P:(DE-He78)aa0526e084994adfb97ce634da902be8$$aBrandhorst, Jana$$b3$$udkfz
000304116 7001_ $$aLakes, Jale$$b4
000304116 7001_ $$aWerner, Dominique$$b5
000304116 7001_ $$aKajüter, Hiltraud$$b6
000304116 7001_ $$aKarpinski, Madeleine$$b7
000304116 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b8$$udkfz
000304116 7001_ $$aStang, Andreas$$b9
000304116 7001_ $$aAlbers, Peter$$b10
000304116 773__ $$0PERI:(DE-600)2406159-1$$a10.3238/arztebl.m2025.0081$$gVol. 122, no. 15$$n15$$p401-405$$tDeutsches Ärzteblatt international$$v122$$x1866-0452$$y2025
000304116 909CO $$ooai:inrepo02.dkfz.de:304116$$pVDB
000304116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8ce1da94e91296e574e4849cfabd230$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000304116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)aa0526e084994adfb97ce634da902be8$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000304116 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000304116 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000304116 9141_ $$y2025
000304116 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDTSCH ARZTEBL INT : 2022$$d2025-01-07
000304116 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000304116 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000304116 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000304116 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000304116 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000304116 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000304116 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bDTSCH ARZTEBL INT : 2022$$d2025-01-07
000304116 9201_ $$0I:(DE-He78)M110-20160331$$kM110$$lEpidemiologisches Krebsregister BW$$x0
000304116 980__ $$ajournal
000304116 980__ $$aVDB
000304116 980__ $$aI:(DE-He78)M110-20160331
000304116 980__ $$aUNRESTRICTED